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Abstract. Malaria clinical studies entailing the experimental infection of healthy volunteerswithPlasmodium parasites
by bites from infected mosquitos, injection of cryopreserved sporozoites, or injection of blood-stage parasites provide
valuable information for vaccine and drug development. Success of these studies depends on maintaining safety. In this
mini-review, we discuss the safety risks and associatedmitigation strategies of these three types of experimental malaria
infection. We aimed to inform researchers and regulators who are currently involved in or are planning to establish
experimental malaria infection studies in endemic or non-endemic settings.
INTRODUCTION
Experimental infection of healthy volunteers with Plas-
modium parasites caused by bites from infected mosqui-
tos, injection of cryopreserved sporozoites, or injection of
blood-stage parasites is being increasingly carried out to
assist development of malaria vaccines1–4 and drugs.5–7 As
well, these studies provide valuable insights into parasite
biology8,9 and the host–parasite interaction.8,10,11 These
studies have been commonly referred to as controlled hu-
manmalaria infection studies. The use of this term has been
subject to recent debate. In this mini-review, we use the
termmalaria volunteer infection studies (VISs) to conform to
the nomenclature adopted by the Medicines for Malaria
Venture. As in other areas of research, the safe use and
containment of infectious material and the mitigation of
other potentially hazardous biological risks are essential to
protect study subjects, staff conducting these studies, and
the wider community. In this mini-review, we discuss the
safety risks to these three groups and the techniques used
to mitigate these risks and maintain the acceptability of
malaria VISs conducted in endemic and non-endemic
settings.
Types of malaria VIS. Of the three types of malaria VISs,
bites from an infected mosquito (mosquito challenge) rep-
resent the most natural method. Anopheles mosquitos,
typically laboratory-reared Anopheles stephensi, are ren-
dered infectious by feeding on in vitro–cultured Plasmodium
falciparum, or in the case of Plasmodium vivax by feeding on
infected patients because in vitro culture is not possible.12 A
less natural mode of infection is needle-based intravenous
inoculation with aseptic purified cryopreserved sporozoites.
Currently, only P. falciparum cryopreserved sporozoites are
available, but it is that possible cryopreserved sporozoites
will become available for other Plasmodium species. Finally,
inducedblood-stagemalaria (IBSM) involves the intravenous
injection of malaria-infected red blood cells (RBCs). Each
method has safety risks and mitigation strategies (summa-
rized in Table 1).
RISKS TO SUBJECTS
Cross infection. Human malaria parasite (HMP) banks are
collections of malaria parasites contained within human blood
products13 and can be used as the ultimate source of parasites
for all three types of malaria VISs. Currently, in vitro culture is
onlypossible forP. falciparum14 andPlasmodiumknowlesi,15,16
with the latter not having been used for VISs in the modern era.
In vitro culture permits the production of P. falciparum HMP
banks under good manufacturing practice conditions, thereby
permitting the selection of parasite strains for all types of
P. falciparum VISs, and blood type for IBSM.13,17 Human
malaria parasite banks produced through continuous in vitro
culture must be tested for adventitious agents as required by
regulatory agencies.
Humanmalaria parasite banks canbeproduced fromdonors
(ex vivo fromparasitemic volunteers infected viamosquitobites
or from IBSM from existing banks, or by collection of para-
sitemic blood from naturally infected individuals [returned
travelers with malaria]), and providing donors are adequately
screened. Donors should complete a lifestyle questionnaire to
identify risk factors for transfusion-transmitted diseases (e.g.,
blood-borne viruses, prion diseases, Q-fever, leptospirosis,
brucellosis, and Chagas disease). At our center, this question-
naire is based on the eligibility criteria for blood donation in
Australia. Donors for HMP banks are screened, using sensitive
PCR and serology assays, for a wide range of blood-borne
viruses (HIV1 and2, humanT-lymphotropic virus, Epstein–Barr
virus [EBV], cytomegalovirus [CMV], hepatitis C, hepatitis B,
parvovirus B19, West Nile virus, Ross River virus, Barmah
Forest virus, dengue fever, and human herpes virus 6 and 7).
The presence of active blood-borne disease or serological ev-
idence of latent infection that can reactivate (e.g., CMV) is ex-
clusionary. Leukodepletion of collected blood is routinely
practiced and provides an additional level of security by re-
moving cell-associated herpes viruses, such as CMV and
EBV,18 that are carried by leukocytes. The absence ofCMVand
EBV isconfirmedbyPCRtestingof thedonor unit ofblood, thus
decreasing the need to match the serostatus of the donor and
recipient forCMVandEBV.BecauseP. vivaxcannotbecultured
in vitro, mosquito bite inoculation can only occur if the mos-
quitos have been fed on infected donors. Therefore, these in-
fected donors may require screening for other diseases
transmitted by An. stephensi mosquitos, including lymphatic
filariasis. Although filarial parasites could theoretically be
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transmitted by blood transfusion, microfilariae transmitted this
way cannot develop into adult worms,19 and thus, the risk of
harm in such an unlikely circumstance is extremely low.20,21
At our center, HMP banks are tested before release using a
process that has undergone regulatory review. This includes
testing for microbial contamination and endotoxins. Whole
genome sequencing of HMP banks can identify contaminants
as well as parasite genotype, clonality, and polymorphisms
associated with antimalarial sensitivity.22,23
Transfusion reaction. A transfusion reaction is a risk spe-
cific to IBSM VISs. The IBSM process inevitably results in
transfusion of a small number of RBCs (up to 1.5 × 109 in the
case ofP. vivax IBSMat our center), which is equivalent to less
than 1 mL of whole blood. Subjects are only inoculated with a
compatible ABOblood group (and compatible rhesus group in
the case of women of childbearing potential). It is remotely
possible that the receipt of donor RBCs could precipitate a
transfusion reaction or cause development of alloantibodies,
which may make future blood transfusion more difficult or
result in hemolytic disease of the newborn, if a woman de-
velops alloantibodies because of this process before be-
coming pregnant. Acute transfusion reactions are judged to
be extremely unlikely because of the very small volume of
blood that is administered with the challenge agent and be-
cause white cells are removed by leukodepletion during pro-
cessing. No acute transfusion reactions have been reported in
more than 350 subjects who have been infected through
IBSM. Nevertheless, subjects are monitored for transfusion
reactions after receiving the challenge agent. Subjects are
screened before inoculation and at the end of the study for
RBC alloantibodies. Two subjects have been reported to de-
velop RBC alloantibodies in the context of IBSM. One was
injectedwithP. falciparum 3D7–infected bloodgroupO (RhD)-
negative RBCs and developed an anti-E antibody at the end of
study blood sampling (Australian and New Zealand Clinical
Trial Registry [ANZCTR] ID: ACTRN12614000781640). Ad-
sorption studies confirmed the presence of a true anti-E allo-
antibody. No irregular anti-RBC antibodies were detected in a
TABLE 1
Summary of safety risks and mitigation strategies in malaria VIS
Safety risk Type of VIS in which risk occurs Mitigation strategies for risk
Transfusion-related infections IBSM Screening and microbial contamination
testing of HMP bank and the challenge
agent
Leukodepletion of HMP bank
Coinfection with other malaria species Mosquito, sporozoite, IBSM Donors screened to exclude mixed
malaria infection
Coinfection with filariasis Mosquito P. vivax Donors screened for filariasis
Transfusion reaction IBSM RBC antibody negative at screening
Inoculation of subjects with the
compatible blood group and rhesus
type
Small numbers of RBCs in the challenge
agent
Alloimmunization IBSM Inoculation of subjects with compatible
blood group and rhesus type
RBC antibody negative at the end of the
study.
Higher malaria inoculation dose than
planned
Mosquito, sporozoite, IBSM Five infectious bites (mosquito)
Manufacturing process controls for
consistent inoculation dose
(sporozoite67 and IBSM)
Cardiac inflammation Mosquito, sporozoite, IBSM Exclusion of subjects at increased risk of
cardiovascular disease
Relapse from P. vivax hypnozoites Mosquito P. vivax Exclusion of subjects with low
cytochrome P-450 isoenzyme 2D6 and
G6PD activity at screening
Primaquine or tafenoquine treatment at
the end of the study
Hemolysis from primaquine or
tafenoquine treatment
Mosquito P. vivax, sporozoite P. vivax G6PD testing at screening
Exposure of study staff to infectious
materials
Mosquito, sporozoite, IBSM Standard personal protective equipment
Onward malaria transmission Mosquito, sporozoite, IBSM Confinement
Travel restriction
Use of a gametocidal agent
qPCR negative at the end of the study
Blood donation restrictions
Insect avoidance
In endemic setting studies, caution with
the use of genetically modified
parasites or a strain not endemic to the
area
Escape of infected mosquitos Mosquito, sporozoite, IBSM (with
transmission studies)
Insectary controls
G6PD=glucose-6-phosphatedehydrogenase;HMP=humanmalariaparasite; IBSM= inducedblood-stagemalaria; qPCR=quantitativepolymerasechain reaction;P. vivax=Plasmodiumvivax;
RBC = red blood cell; VIS = volunteer infection studie.
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sample taken6weeksearlier. In addition, theRBCs in theHMP
bank were documented to lack the E antigen. Although anti-E
antibodies have been implicated in hemolytic transfusion
reactions,24,25 it is well established that natural anti-E antibodies
may occur without transfusion.26,27 A transfusion medicine expert
concluded it was most likely that this subject had naturally occur-
ring low-levelanti-Ealloantibodiesandthat itwasunlikely that these
alloantibodies were induced in the study. The second subject
participated in a vaccine study inwhich theywere injectedwith 3 ×
107 chemically attenuated asexual whole P. falciparum parasites
containedwithin blood groupO (RhD)-negative RBCs.28 Parasites
were derived from cultures with 5% parasitemia, making the total
numberof injectedRBCs6×108.Thissubjectwas theonlysubject,
of six subjects, who developed antibodies to theminor Rh antigen
c.Whether thiswas related in someotherway topreparationof the
vaccine is unknown. The authors suggested reducing the number
of RBCs per inoculum to decrease the risk of induction of alloan-
tibodies.28 It is not clear why the vaccine induced an antibody
response, although there have been no such cases within
IBSM studies with P. vivax (44 subjects)29,30 (ANZCTR ID:
ACTRN12617001502325; ANZCTR ID: ACTRN12616000174482;
ClinicalTrials.gov ID: NCT02573857) or Plasmodiummalariae (two
subjects),31 where means of 6.5 × 108 and 6.8 × 108 RBCs were
administered per challenge agent syringe, respectively.
Dose of parasites. The number of parasites injected (i.e.,
the dose) is a determinant of the starting blood-stage para-
sitemia. When infection is induced by sporozoite inoculation,
the number of infected hepatocyteswill determine the starting
blood-stage parasitemia,32,33 whereas in IBSM, it is the actual
number of parasites injected. Mosquito bite VISs typically in-
volvesfivebitesby infectiousmosquitos.However, this entails
uncertainty regarding the dose a subject receives, which can
vary by several thousand sporozoites.34–36 Each sporozoite
that successfully establishes liver-stage infection results in
the production of 25,000–30,000 merozoites destined to in-
vade RBCs. Thus, this variation can significantly impact the
ultimate blood-stage challenge agent and the time to patency.
The use of PCR instead of microscopy reduces the time to
patency and enablesmore prompt diagnosis and treatment of
malaria for all forms of malaria VISs.37 For VISs using cry-
opreserved sporozoites or IBSM, the challenge agent can be
better controlled to produce a more reproducible dose (which
means less variation in parasitemia between VIS subjects)
than possible in mosquito bite VISs.32,38 This theoretically
results in awell-characterized anduniformpatternof growthof
parasitemia in vivo. In theory, a single viable parasite is all that
is needed,with the duration of theprepatent period depending
on the challenge agent dose.
Serious adverse events. Three episodes of cardiac in-
flammation have been reported in malaria VISs. All three
subjects had been infected by mosquito bites in the Nether-
lands; however, it is not clear whether these cardiac events
were related to the malaria infection.4,39,40 As a precaution,
individuals with significant cardiovascular disease risk factors
are excluded at screening in VISs.
Relapse of P. vivax. For P. vivax mosquito bite VISs, re-
searchers must ensure no liver-stage hypnozoites remain at the
end of the study. Although radical curewith primaquine had been
considered satisfactory for this purpose, two subjects experi-
enced multiple relapses of P. vivax following challenge via mos-
quitobitesdespitechloroquineandprimaquine treatment.1These
relapses were discovered to be caused by a previously
unrecognized pharmacogenetic effect of polymorphism in the
human cytochrome P-450 isoenzyme 2D6 (CYP2D6).41 Both
subjectswereshown tohave lowactivity ofCYP2D6 that resulted
in them not transforming primaquine into its active metabolite.
Therefore, individuals who are poor or intermediate metabolizers
of CYP2D6 should not be enrolled in such studies. In addition,
individualswith glucose-6-phosphate dehydrogenase deficiency
(G6PDd) should be excluded from sporozoite-induced P. vivax
VISs as they cannot receive primaquine because of the risk of
hemolysis. Female heterozygotes may also experience clinically
significant hemolysis if moderate deficiency is not excluded by a
quantitative assay.42 Currently, it is not clear whether poor
CYP2D6 activity also affects the activity of primaquine against
gametocytes.43 Although tafenoquine (a recently registered
8-aminoquinoline) may represent an alternative to primaquine,
tafenoquine can also cause life-threatening hemolysis in individ-
uals with G6PDd. Furthermore, because of its long half-life, the
hemolytic effects of tafenoquine cannot be limited by halting
treatment as can be practiced with primaquine as tafenoquine
is a single-dose regime.44 Thus, a higher threshold of glucose-6-
phosphate dehydrogenase activity in female heterozygotes
(> 70%) is required compared with primaquine (> 30%).42
RISKS TO STAFF
Malaria infection. Risks to staff performing VISs include
bites from an infected mosquito or inadvertent exposure to
infectious material such as a needlestick injury in cry-
opreserved sporozoite studies and IBSMstudies. Staff should
use appropriate personal protective equipment and have clear
guidelines on how to access an infectious disease physician
for advice regarding malaria-specific treatment.
RISKS TO THE COMMUNITY
Malaria transmission. Preventing onward transmission of
malaria is vital. Malaria VISs have historically been conducted
at a small number of research centers in non-endemic coun-
tries with high levels of physical containment and health in-
frastructure (Australia, the Netherlands, the United Kingdom,
and the United States). At our center in Brisbane, Australia,
subjects are inoculated at least 8 days before receiving any
therapeutic intervention. Whereas P. vivax produces game-
tocytes early in infection,45 P. falciparum gametocytes typi-
cally appear in the circulation 10 days after inoculation.11
Subjects potentially infectious to mosquitos may be confined
indoors to ensure they are not bitten by vector-competent
Anopheles mosquitos. More commonly, subjects are moni-
tored as outpatients37 and required to adhere to travel re-
strictions. At our center, subjects are required not to travel in
the period between inoculation and curative treatment, to
malaria-endemic countries or to northern Australia where
Anopheles farauti (the Australian malaria vector) is present.46 In
Queensland, An. farauti mosquitos are not found south of
Mackay, 950 km north of Brisbane. No vector-competent
Anopheles mosquitos are found in Oxford, United Kingdom, or
Nijmegen, the Netherlands, although these mosquitos were
once endemic in both cities.47,48 The vector-competent species
Anopheles quadrimaculatus is endemic to the east coast of
North America49,50 and could conceivably result in local trans-
mission in the context of VISsundertakenat centers inMaryland.
Climate changemodels havepredicted the expansion ofmalaria
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transmissionzones inAustralia,Europe,andNorthAmerica,51 so
researchersmust remain vigilant of such changes and alter their
practices accordingly.
Mitigation strategies to prevent onward transmission may
need to be applied at the end of themalaria VIS, if infection has
resulted in the development of gametocytemia. Subjects may
require treatment with an appropriate gametocytocidal agent
(e.g., primaquine) before exiting the trial. Parasite-negative
status can be confirmed using quantitative polymerase chain
reaction (qPCR) assays that detect both asexual parasites and
gametocytes, which are increasingly being used to confirm
subjects whether are parasite-negative before they exit a
malaria VIS.52,53 The 18S qPCR used at our center has a limit
of quantitation of 111 parasites/mL. To transmit malaria in a 1-
μL mosquito blood meal, the female Anopheles mosquito
needs to take up onemale and one female gametocyte. Thus,
it is extremely unlikely that a subject would transmit malaria
with a negative 18S qPCR result. Additional gametocyte-
specific qRT-PCR assays, such as one that targets pfs25 (the
abundant mRNA present in female gametocytes), can also be
used to confirm the absence of gametocytes.54 Strict en-
forcement of travel restrictions during the study and qPCR
confirmation of parasite negativity before the end of study are
essential, particularly if the study entails the deliberate in-
duction of higher gametocyte levels to test transmission
blocking interventions.11 Study subjects are not permitted to
donate blood until 6 months after the end of the study in
Australia, or 3 years in the United States.
Mosquito escape. Escape of a malaria-infected mosquito
could result in difficult-to-diagnose and potentially fatal local
malaria.Furthermore, the local establishmentofanexoticmalaria
vector would represent a serious breach of biocontainment.
Recently updated guidelines from the American Society of
TropicalMedicine andHygiene provide strategies tomitigate the
risk of arthropod escape.55 The primary method is the use of an
appropriately secure insectary. Standard operating procedures
for mosquito handling and recovery in the event of mosquito
escape are required to prevent and rectify mosquito escape.
Genetically modified parasites. Additional regulations,
specific to each national jurisdiction, apply to the use and po-
tential release of genetically modified parasite pathogens. This
includes genetically modified malaria parasites that have been
used inclinical trials56,57 (ANZCTR ID:ACTRN12617000824369).
The inadvertent release of genetically modified parasites into
local malaria vectors could lead to unforeseen or additional
negative effects beyond that causedby the release of awild type
organism.
Risksof conductingmalariaVIS inendemic settings.The
development of malaria VISs in endemic settings represents an
important advance in terms of studying infection in naturally
exposed populations58,59 but imposes additional logistic and
ethical considerations.Confinementof studysubjects from initial
infection to clearanceof parasitemia hasbeenone strategyused
tomitigate additional risks.58 Ideally, the aimwould be to ensure
the availability of equivalent containment measures and, if pos-
sible, qPCR to ensure equivalent biocontainment and subject
safety60,61 to what is practiced in settings with more advanced
health infrastructure. Cryopreserved sporozoite inoculation has
been the preferred mode of infection in recent VISs in malaria-
endemicsettings58,62 becauseof the infrastructure requirements
of mosquito bite VISs (insectary maintenance) and IBSM VISs
(clean room facilities for malaria challenge agent preparation).
Although measures to mitigate the risk of onward trans-
mission of malaria from gametocytemic subjects to local
mosquitos or the escape of infectious or noninfectious exotic
mosquitos do not differ conceptually,63 containment mea-
sures should be equally rigorous. As P. vivax infection results
in the production of transmissible gametocytemia early in in-
fection,64 confinement of subjects needs to begin at the onset
of parasitemia. The unintentional release of a genetically
modified parasite or a strain not endemic in the area, espe-
cially a parasite associatedwith artemisinin resistance suchas
a drug-resistant P. falciparum isolate (e.g., a kelch13mutation
such as used in an IBSM VIS conducted at our center;
ANZCTR ID: ACTRN12617001394336), would represent a
severe breach of biosecurity. Previous exposure to malaria
reduces the incidence and severity of adverse events in en-
demic VIS settings.62 However, the spectrum of adverse
events in endemic populations is less well studied, and close
monitoring is still required.65 Practical considerations such as
clinical immunity masking the onset of parasitemia and the
effect of immunity on the appearance of gametocytemia and
time of infectiousness should also be considered.11,66
CONCLUSION
In the context of malaria VISs, it is not enough to react to
safety concerns as they occur. Researchers must remain
vigilant to potential risks including new risks induced by cli-
mate changes, changes in regulations, and new genetically
modified parasites so as to ensure high safety standards vital
to the safe conduct of malaria VISs. Furthermore, maintaining
an intact reputation of malaria VIS is essential for ongoing
support from the scientific community, regulators, the general
community, and, most importantly, the subjects.
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